Previous Close | 166.61 |
Open | 161.64 |
Bid | 152.78 x 600 |
Ask | 153.28 x 100 |
Day's Range | 148.50 - 164.73 |
52 Week Range | 62.55 - 170.47 |
Volume | |
Avg. Volume | 3,972,122 |
Market Cap | 58.712B |
Beta (5Y Monthly) | 1.57 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -14.34 |
Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 137.59 |
The drop comes as Moderna awaits important developments involving its experimental cancer treatment, a new respiratory vaccine, and a possible avian flu vaccine under development.
Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.
Key Insights The projected fair value for Moderna is US$294 based on 2 Stage Free Cash Flow to Equity Current share...